Posted by Michael Wonder on 18 Dec 2019
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
16 December 2019 - GSK confirms submission of a biologics license application to the US FDA.
In 2017, GSK2857916 was granted breakthrough therapy designation from the US FDA and PRIME designation from the EMA.
